Aclaris reports Q1 net loss $15.1M, cash runway extended to H1 2028; multiple pipeline milestones ahead

Aclaris Therapeutics, Inc.

2025-Q1 EPS reported -$0.12 revenue$1,455,000

Q1 net loss $15.1M vs $16.9M YoY; revenue $1.5M vs $2.4M; cash $190.5M as of March 31, 2025.
Cash runway extended through first half of 2028, fully funding preclinical and clinical plans.
Bosakitug Phase 2 in atopic dermatitis to start Q2 2025; seeking partners for respiratory indications.
ATI-2138 Phase 2a AD top line results expected June 2025; ATI-052 IND cleared, Phase 1 starting Q2 2025.
Jesse W. Hall appointed CMO; Sun Pharma injunction lifted, offering potential non-dilutive financing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.